MarginsXMarginsX
Home › Markets › Health Care › LKFT

Lakefront Biotherapeutics (LKFT)

LKFT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$34.79
+2.38% on the day
Market cap
$2.3B
Mid cap
Revenue · 2025
$1.2B
No prior year to compare
Net income · 2025
$354.6M
28.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/0001104659-26-035163-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerLKFT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryBelgium
IPO year2015
SEC CIK0001421876
SEC industry codePharmaceutical Preparations
Incorporated inBelgium

Financials · 2025

LineValue
Revenue$1.2B
Net income$354.6M
Operating income$326.1M
Net margin28.9%
Operating margin26.5%
Revenue growthNo prior-year revenue to compare
Cash$97.1M
Total assets$3.8B
P/E (computed)6.5×
P/S (computed)1.9×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
4.1 months
$97.1M cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed March 26, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-03-26
Cash and burn$97.1M cash; operating cash flow -$71.1M a quarter.Report 2025-12-31
Shares outstanding65,897,071 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorBDO Bedrijfsrevisoren - BDO Réviseurs d'Entreprises, Zaventem, BelgiumPCAOB Form AP 2026-04-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$1.2B$354.6M-$284.5M$97.1MNo debt tags$1.2B20-F 2026-03-26

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-05-08
Latest annual report20-F2026-03-26
Latest quarterly / interim
FORM 6-K
6-K2026-11-16

Source: SEC EDGAR submissions feed, 548 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+1.6%
1 month+17.0%
3 months+21.2%
Year to date+3.9%
1 year+7.9%
From 52-week high-1.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B
PHVSPharvaris N.V.$32.44-2.76%$2.3B
NAMSNewAmsterdam Pharma Company N.V.$19.46-3.38%$2.3B
PRGOPerrigo Company plc$16.18-0.37%$2.2B
RCUSArcus Biosciences Inc.$16.86-3.27%$2.4B
PVLAPalvella Therapeutics Inc.$144.60-5.17%$2.1B
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier